JP2022547167A5 - - Google Patents
Info
- Publication number
- JP2022547167A5 JP2022547167A5 JP2022515487A JP2022515487A JP2022547167A5 JP 2022547167 A5 JP2022547167 A5 JP 2022547167A5 JP 2022515487 A JP2022515487 A JP 2022515487A JP 2022515487 A JP2022515487 A JP 2022515487A JP 2022547167 A5 JP2022547167 A5 JP 2022547167A5
- Authority
- JP
- Japan
- Prior art keywords
- cntfr
- kras
- pharmaceutical composition
- composition according
- mutated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025088861A JP2025138641A (ja) | 2019-09-10 | 2025-05-28 | Ｋｒａｓ変異型がんを治療する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898249P | 2019-09-10 | 2019-09-10 | |
| US62/898,249 | 2019-09-10 | ||
| US201962931608P | 2019-11-06 | 2019-11-06 | |
| US62/931,608 | 2019-11-06 | ||
| PCT/US2020/050206 WO2021050732A1 (en) | 2019-09-10 | 2020-09-10 | Methods of treating kras mutant cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025088861A Division JP2025138641A (ja) | 2019-09-10 | 2025-05-28 | Ｋｒａｓ変異型がんを治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022547167A JP2022547167A (ja) | 2022-11-10 |
| JP2022547167A5 true JP2022547167A5 (https=) | 2023-09-15 |
Family
ID=74866476
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515487A Pending JP2022547167A (ja) | 2019-09-10 | 2020-09-10 | Ｋｒａｓ変異型がんを治療する方法 |
| JP2025088861A Pending JP2025138641A (ja) | 2019-09-10 | 2025-05-28 | Ｋｒａｓ変異型がんを治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025088861A Pending JP2025138641A (ja) | 2019-09-10 | 2025-05-28 | Ｋｒａｓ変異型がんを治療する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220331401A1 (https=) |
| EP (1) | EP4028044A4 (https=) |
| JP (2) | JP2022547167A (https=) |
| KR (1) | KR20220061997A (https=) |
| CN (1) | CN114375197A (https=) |
| AU (1) | AU2020346820A1 (https=) |
| CA (1) | CA3149872A1 (https=) |
| WO (1) | WO2021050732A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018106790A1 (en) * | 2016-12-06 | 2018-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Ciliary neurotrophic factor receptor ligand-binding agents and methods of using the same |
| WO2018128745A1 (en) * | 2017-01-06 | 2018-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Ciliary neurotrophic factor receptor ligands and methods of using the same |
-
2020
- 2020-09-10 WO PCT/US2020/050206 patent/WO2021050732A1/en not_active Ceased
- 2020-09-10 KR KR1020227010002A patent/KR20220061997A/ko active Pending
- 2020-09-10 US US17/639,525 patent/US20220331401A1/en active Pending
- 2020-09-10 EP EP20863554.0A patent/EP4028044A4/en active Pending
- 2020-09-10 JP JP2022515487A patent/JP2022547167A/ja active Pending
- 2020-09-10 CN CN202080063707.0A patent/CN114375197A/zh active Pending
- 2020-09-10 CA CA3149872A patent/CA3149872A1/en active Pending
- 2020-09-10 AU AU2020346820A patent/AU2020346820A1/en active Pending
-
2025
- 2025-05-28 JP JP2025088861A patent/JP2025138641A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022547167A5 (https=) | ||
| JP7219791B2 (ja) | Ｒｔｋ突然変異細胞を有する患者を処置するための組成物及び方法 | |
| US20220307013A1 (en) | Gene fragment overexpression screening methodologies, and uses thereof | |
| JP2023518038A5 (https=) | ||
| Döring et al. | R ab33 B and its autophagic A tg5/12/16 L 1 effector assist in hepatitis B virus naked capsid formation and release | |
| EP1021464B1 (en) | Cellular receptor for hiv-1 vpr essential for g2/m phase transition of the cell cycle | |
| Kübler et al. | Large set data mining reveals overexpressed GPCRs in prostate and breast cancer: Potential for active targeting with engineered anti-cancer nanomedicines | |
| KR20180096621A (ko) | 암의 치료용 조합물 | |
| Li et al. | Targeting protein-protein interaction with covalent small-molecule inhibitors | |
| AU2010218261B2 (en) | Compositions and methods for visualizing and eliminating cancer stem cells | |
| Maekawa et al. | Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population | |
| CN103298481A (zh) | 用于治疗卵巢癌的催乳素受体拮抗剂和化疗药物的用途 | |
| JP2004533825A5 (https=) | ||
| WO2018022637A1 (en) | Crebbp related cancer therapy | |
| US20080159992A1 (en) | Hepatocyte growth factor receptor splice variants and methods of using same | |
| WO2022039026A1 (ja) | 人工タンパク質、Ｒａｓ阻害剤及び抗がん剤 | |
| ES2693080T3 (es) | Mutaciones en el dominio extracelular III del gen del receptor del factor de crecimiento epidérmico | |
| WO2021055846A1 (en) | Methods and compositions for treating myc-driven cancers | |
| EP2515930A1 (en) | Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells | |
| KR20260022498A (ko) | 암의 치료 및 예방을 위한 조합물 | |
| Blomquist et al. | Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression | |
| JP2019536802A5 (https=) | ||
| Toh et al. | Genetic variations of the SLC22A4 gene in Chinese and Indian populations of Singapore | |
| WO2021257961A1 (en) | Compositions and methods for treating cancer | |
| EP4584286A1 (en) | Targeted pd-l1 degradation |